This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. A warning letter posted Tuesday by the Food and Drug ...
Dexcom faces mounting scrutiny over G7 safety concerns, FDA violations, financial practices, and growing competition from ...
DexCom is building increasingly user-friendly devices that continuously monitor blood glucose levels, and a new collaboration between DexCom and Google could lead to the smallest such devices yet.
LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
The diabetes tech firm tailored its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin. The device is similar to existing prescription CGMs. Users pair the ...
The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin.
StockStory.org on MSN
Why DexCom (DXCM) Shares Are Trading Lower Today
Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback